Tag: Nirsevimab RSV

All

Latest

FDA to Review Nirsevimab for RSV Prevention in Kids Under 2

The FDA has accepted for review AstraZeneca’s biologics license application for nirsevimab for the prevention of RSV lower respiratory tract disease in newborns and infants entering or during their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found